Clonotypic PCR correlated with clinical status at maximal response
| Patient . | Relative disease burden per 100 ng DNA . | |||
|---|---|---|---|---|
| Pretreatment/source of DNA assayed . | Post-treatment/source of DNA assayed . | Flow cytometry (PB and BM) . | Treatment response . | |
| 6 | 10−4/PB, BM | 10−4/PB, BM | + | PR |
| 11 | 10−5/PB, BM | 10−4/BM | + | PR |
| 12 | 10−5/PB, BM | 10−5/BM | + | PR |
| 19 | 10−4/PB, BM | 10−7/BM | Not done | PR |
| 22 | 10−3/PB, 10−5/BM | 10−5/BM | + | PR |
| 2 | 10−5/PB | 100/BM | − | nPR |
| 4 | 10−4/BM | 10−2/BM | − | nPR |
| 7 | 10−5/PB | 10−5/BM | − | nPR |
| 10 | 10−4/BM | Positive/BM* | + | nPR |
| 13 | 10−4/LN | Positive/BM† | + | nPR |
| 26 | 10−3/BM‡ | 10−2/BM | + | CR |
| 28 | >100 (600 ng)/BM | Negative/BM | − | CR |
| 1 | 10−5/PB | 10−1/BM | − | CR |
| 16 | Inevaluable/PB1-153 | Inevaluable1-153 | − | CR |
| 17 | Inevaluable1-153 | Inevaluable1-153 | − | CR |
| 23 | 10−3/BM 10−5/PB | 100/BM 10−3/PB | − | CR |
| 25 | 10−4/BM | Negative | − | CR |
| 27 | 10−4/BM | Negative/BM | − | CR |
| 30 | 10−2/BM | Negative/BM | − | CR |
| Patient . | Relative disease burden per 100 ng DNA . | |||
|---|---|---|---|---|
| Pretreatment/source of DNA assayed . | Post-treatment/source of DNA assayed . | Flow cytometry (PB and BM) . | Treatment response . | |
| 6 | 10−4/PB, BM | 10−4/PB, BM | + | PR |
| 11 | 10−5/PB, BM | 10−4/BM | + | PR |
| 12 | 10−5/PB, BM | 10−5/BM | + | PR |
| 19 | 10−4/PB, BM | 10−7/BM | Not done | PR |
| 22 | 10−3/PB, 10−5/BM | 10−5/BM | + | PR |
| 2 | 10−5/PB | 100/BM | − | nPR |
| 4 | 10−4/BM | 10−2/BM | − | nPR |
| 7 | 10−5/PB | 10−5/BM | − | nPR |
| 10 | 10−4/BM | Positive/BM* | + | nPR |
| 13 | 10−4/LN | Positive/BM† | + | nPR |
| 26 | 10−3/BM‡ | 10−2/BM | + | CR |
| 28 | >100 (600 ng)/BM | Negative/BM | − | CR |
| 1 | 10−5/PB | 10−1/BM | − | CR |
| 16 | Inevaluable/PB1-153 | Inevaluable1-153 | − | CR |
| 17 | Inevaluable1-153 | Inevaluable1-153 | − | CR |
| 23 | 10−3/BM 10−5/PB | 100/BM 10−3/PB | − | CR |
| 25 | 10−4/BM | Negative | − | CR |
| 27 | 10−4/BM | Negative/BM | − | CR |
| 30 | 10−2/BM | Negative/BM | − | CR |
Results of semiquantitative clonotypic PCR at pretreatment and post-treatment time-points are presented along with clinical response. Results of PCR are reported as the 10-fold serial end-point dilution of 100 ng (roughly 104 cell equivalents), which still yielded a positive PCR result on the semi-nested round of PCR. Hence, there is an inverse relation between the disease burden and the serial dilution reported positive. The more dilute the specimen recorded as positive, the greater the disease burden.
Paraffin section used as source of DNA; only qualitative result available.
Bone marrow aspirate slide used as a source of DNA; only qualitative result available.
s/p 3 cycles fludarabine; no pretreatment available.
Primers problematic (see text).